News and Press Releases
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance
Latest real-world metric in Phesi’s AI-driven Trial Accelerator quantifies patient burden to unlock a patient-centric approach to trial design and implementation 7 May 2024 -- Boston, US -- Phesi, a...
Category: Clinical Trials
Posted: May 7, 2024
Gilead Sciences Appoints Peter Wickersham to Vice-President and General Manager in the UK and Ireland
7 May 2024 -- London, UK -- Gilead Sciences announced today the appointment of Peter Wickersham as vice-president and general manager for the UK and Ireland. In his new role,...
Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024
New high-throughput device to unlock the potential of advanced materials
7 May 2024 -- Birmingham, UK -- A Birmingham researcher has developed a new high-throughput device that produces libraries of nanomaterials, using sustainable mechanochemical approaches. Dr Jason Stafford from the...
Category: BioManufacturing
Posted: May 7, 2024
London Biotechnology Show opens its doors tomorrow at Olympia West
7 May 2024 – London, UK – The most-awaited London Biotechnology Show will finally open its doors tomorrow at Olympia West, London, UK. #LBS24 is a 2 day conference &...
Category: Biotechnology, Drug Delivery, Drug Discovery, Manufacturing and Packing, Pharmaceutical
Posted: May 7, 2024
Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research
Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis 07 May 2024 -- Cambridge and London,...
Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024
Unit AB3-04, Level 3 BioData Innovation Centre Wellcome Genome Campus Hinxton Cambridge, CB10 1DR
ELRIG UK Announces Profs Ijeoma Uchegbu and Marcus Schindler as keynote speakers at Drug Discovery 2024
Drug Discovery 2024: Connecting Minds, Transforming Science, Empowering Community will take place at ExCeL London from 2–3 October 2 May 2024 – Cambridge, UK – The European Laboratory Research &...
Category: Biotechnology, Drug Discovery
Posted: May 7, 2024
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site
6 May 2024 -- Minnesota, US, and Missouri, US -- Kindeva Drug Delivery, a global leader in drug-device combination products, today announced its investment in a second manufacturing line for...
Category: Drug Delivery, Manufacturing and Packing
Posted: May 6, 2024
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations 5 May 2024 -- Beerse, Belgium -- Janssen-Cilag International,...
Category: Clinical Trials, Drug Discovery
Posted: May 5, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
New data from phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus...
Category: Clinical Trials, Drug Discovery
Posted: May 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Phase 2 data for ERLEADA ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100% biochemical free recurrence rate more than two years post-surgery
Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localised prostate cancer (HRLPC) experience disease recurrence within two years of surgery 3 May 2024...
Category: Drug Discovery, Pharmaceutical
Posted: May 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Bespak and H&T Presspart enter into collaboration agreement to advance transition to low GWP propellants in pMDIs
Partnership will provide GMP filling capabilities and development support for clinical trial programmes with low GWP propellants 3 May 2024 -- Holmes Chapel, UK, and Blackburn, UK -- Bespak, a...
Category: Clinical Trials, Drug Delivery
Posted: May 3, 2024
Bespak and Medicines Evaluation Unit collaborate to accelerate clinical trials on climate-friendly inhalers
Relationship will provide pharmaceutical industry with fast route to clinical evaluation of low GWP pMDIs 3 May 2024 -- Holmes Chapel and Manchester, UK -- Bespak, a leading contract development...
Category: Clinical Trials, Drug Delivery
Posted: May 3, 2024
PCI Pharma Services Begins Installation of Sterile Fill-Finish and Lyophilisation Line as Part of $100m New Facility Expansion
Construction and validation activities at leading CDMO’s Bedford, New Hampshire, US, campus will conclude later this year, with GMP production commencing early 2025 2 May 2023 -- Pennsylvania, US --...
Category: BioManufacturing, Manufacturing and Packing
Posted: May 2, 2024
Myonex Closes Creapharm Acquisition Expanding Global Services
2 May 2024 -- Pennsylvania, US -- Myonex has completed the previously announced acquisition of Creapharm’s pharmaceutical services business. This transaction combines capabilities and flexibility to serve pharmaceutical and biotech...
Category: Biotechnology, Pharmaceutical
Posted: May 2, 2024
